Autor(es): Mendes, Tiago ; Cardoso, Sandra ; Guerreiro, Manuela ; Maroco, Joao ; Silva, Dina ; Alves, Luisa ; Schmand, Ben ; Gerardo, Bianca ; Lima, Marisa ; Santana, Isabel ; de Mendonca, Alexandre
Data: 2019
Identificador Persistente: http://hdl.handle.net/10400.1/14464
Origem: Sapientia - Universidade do Algarve
Assunto(s): Alzheimers-Disease; Amyloid-Beta; Older-People; Anosognosia; Diagnosis; Dementia; Association; Population; Prevalence; Depression
Background: The use of biomarkers, in particular amyloid-beta (A(beta) changes, has allowed the possibility to identify patients with subjective memory complaints (SMCs) and amnestic mild cognitive impairment (aMCI) who suffer from Alzheimer's disease (AD). Since it is unfeasible that all patients with aMCI could presently undergo biomarkers assessment, it would be important that SMCs might contribute to identify the aMCI patients who have AD amyloid pathology. Objectives: To know whether aMCI patients with amyloid biomarkers (A beta(+)) present greater SMCs as compared to those without amyloid biomarkers (A beta(-)). Methods: Participants were selected from a cohort of nondemented patients with cognitive complaints and a comprehensive neuropsychological evaluation, on the basis of 1) diagnosis of aMCI
